Progress and Future Challenges of Human Induced Pluripotents Stem Cell in Regenerative Medicine
Abstract
BACKGROUND: Less than a decade ago the prospect for reprogramming the human somatic cell looked bleak at best. It seemed that the only methods at our disposal for the generation of human isogenic pluripotent cells would have to involve somatic cell nuclear transfer (SCNT). Shinya Yamanaka in August 2006 in his publication (Cell) promised to change everything by showing that it was apparently very simple to revert the phenotype of a differentiated cell to a pluripotent one by overexpressing four transcription factors in murine fibroblasts.
CONTENT: Mouse and human somatic cells can be genetically reprogrammed into induced pluripotent stem cells (iPSCs) by the expression of a defined set of factors (Oct4, Sox2, c-Myc, and Klf4, as well as Nanog and LIN28). iPSCs could be generated from mouse and human fibroblasts as well as from mouse liver, stomach, pancreatic, neural stem cells, and keratinocytes. Similarity of iPSCs and embryonic stem cells (ESCs) has been demonstrated in their morphology, global expression profiles, epigenetic status, as well as in vitro and in vivo differentiation potential for both mouse and human cells. Many techniques for human iPSCs (hiPSCs) derivation have been developed in recent years, utilizing different starting cell types, vector delivery systems, and culture conditions. A refined or perfected combination of these techniques might prove to be the key to generating clinically applicable hiPSCs.
SUMMARY: iPSCs are a revolutionary tool for generating in vitro models of human diseases and may help us to understand the molecular basis of epigenetic reprogramming. Progress of the last four years has been truly amazing, almost verging on science fiction, but if we can learn to produce such cells cheaply and easily, and control their differentiation, our efforts to understand and fight disease will become more accessible, controllable and tailored. Ability to safely and efficiently derive hiPSCs may be of decisive importance to the future of regenerative medicine.
KEYWORDS: iPSCs, ESC, reprogramming factor, reprogramming efficiency, somatic cell
Full Text:
PDFReferences
Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448: 313-7, CrossRef.
Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007; 448: 318-24, CrossRef.
Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007; 1: 55-70, CrossRef.
Rideout WM III, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002; 109: 17-27, CrossRef.
Campbell KH, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature. 1996; 380: 64-6, CrossRef.
Jaenisch RN. Human cloning - The science and ethics of nuclear transplantation. N Engl J Med. 2004; 351: 2787-91, CrossRef.
Egli D, Rosains J, Birkhoff G, Eggan K. Developmental reprogramming after chromosome transfer into mitotic mouse zygotes. Nature. 2007; 447: 679-85, CrossRef.
Cowan CA, Atienza J, Melton DA, Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science. 2005; 309: 1369-73, CrossRef.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76, CrossRef.
Hayden EC. The growing pains of pluripotency. Nature. 2011; 473: 272-4, CrossRef.
Vogel G. Breakthrough of the year: reprogramming cells. Science. 2008; 322: 1766-7, CrossRef.
Mason C, Manzotti E. Induced pluripotent stem cells: an emerging technology platform and the Gartner hype cycle. Regen Med. 2009; 4: 329-31, CrossRef.
Yamanaka S. Pluripotency and nuclear reprogramming. Philos Trans R Soc Lond B Biol Sci. 2008; 363: 2079-87, CrossRef.
Ledford H. In search of a viable business model. Nature Reports Stem Cells. 2008; [n.v]: [n.p], CrossRef.
Gottweis H, Minger S. iPS cells and the politics of promise. Nat Biotechnol. 2008; 26: 271-2, CrossRef.
Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell. 2010; 7: 521-31, CrossRef.
Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and IPSCs during reprogramming and time in culture. Cell Stem Cell. 2011; 8: 106-18, CrossRef.
Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011; 471: 68-73, CrossRef.
Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011; 471: 63-7, CrossRef.
Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Närvä E, et al. Copy number variation and selection during reprogramming to pluripotency. Nature. 2011; 471: 58-62, CrossRef.
Panopoulos AD, Ruiz S, Belmonte JCI. iPSCs: Induced back to controversy. Cell Stem Cell. 2011; 8: 347-58, CrossRef.
Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell. 2010; 143: 508-25, CrossRef.
Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell. 2011; 8: 376-88, CrossRef.
Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008; 451: 141-6, CrossRef.
Hochedlinger K, Jaenisch R. Nuclear transplantation, embryonic stem cells, and the potential for cell therapy. N Engl J Med. 2003; 349: 275-86, CrossRef.
Yang X, Smith SL, Tian XC, Lewin HA, Renard JP, Wakayama T. Nuclear reprogramming of cloned embryos and its implications for therapeutic cloning. Nature Genet. 2007; 39: 295-302, CrossRef.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-72, CrossRef.
Liu X, Huang J, Chen T, Wang Y, Xin S, Li J, et al. Yamanaka factors critically regulate the developmental signaling network in mouse embryonic stem cells. Cell Res. 2008; 18: 1177-89, CrossRef.
Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009; 122: 3502-10, CrossRef.
Li W, Zhou H, Abujarour R, Zhu S, Young Joo J, Lin T, et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cell. 2009; 27: 2992-3000, CrossRef.
Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotech. 2008; 26: 101-6, CrossRef.
Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotech. 2008; 26: 1269-75, CrossRef.
Jincho Y, Araki R, Hoki Y, Tamura C, Nakamura M, Ando S, et al. Generation of genome integration-free induced pluripotent stem cells from fibroblasts of C57BL/6 mice without c-Myc transduction. J Biol Chem. 2010; 285: 26384-9, CrossRef.
Kim JB, Greber B, Arauzo-Bravo MJ, Meyer J, Park KI, Zaehres H, et al. Direct reprogramming of human neural stem cells by Oct4. Nature. 2009; 461: 649-3, CrossRef.
Tsai SY, Clavel C, Kim S, Ang YS, Grisanti L, Lee DF, et al. Oct4 and Klf4 reprogram dermal papilla cells into induced pluripotent stem cells. Stem Cells. 2010; 28: 221-8, CrossRef.
Eminli S, Utikal J, Arnold K, Jaenisch R, Hochedlinger K. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cell. 2008; 26: 2467-74, CrossRef.
Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell. 2008; 3: 340-5, CrossRef.
Yang S, Ha C, Jung M, Jin H, Lee M, Song H, et al. Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy. 2004; 6: 476-86, CrossRef.
Sun N, Longaker MT, Wu JC. Human iPS cell-based therapy: considerations before clinical applications. Cell Cycle. 2010; 9: 880-5, CrossRef.
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318: 1917-20, CrossRef.
Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, Hess C, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell. 2009; 5: 434-41, CrossRef.
Firestone AJ, Chen JK. Controlling destiny through chemistry: Small-molecule regulators of cell fate. ACS Chem Biol. 2009; 5: 15-34, CrossRef.
Hockemeyer D, Soldner F, Cook EG, Gao Q, Mitalipova M, Jaenisch R. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell. 2008; 3: 346-53, CrossRef.
Yamanaka S. Elite and stochastic models for induced pluripotent stem cell generation. Nature. 2009; 460: 49-52, CrossRef.
Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009; 41: 968-76, CrossRef.
Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell. 2008; 133: 250-64, CrossRef.
Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic ß cells into induced pluripotent stem cells. Curr Biol. 2008; 18: 890-4, CrossRef.
Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature. 2009; 462: 595-601, CrossRef.
Sipp D. Gold standards in the diamond age: the commodification of pluripotency. Cell Stem Cell. 2009; 5: 360-3, CrossRef.
Ng HH, Surani MA. The transcriptional and signaling networks of pluripotency. Nat Cell Biol. 2011; 13: 490-6, CrossRef.
Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or selfrenewal of ES cells. Nat Genet. 2000; 24: 372-6, CrossRef.
Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Bio. 2007; 9: 625-35, CrossRef.
Boiani M, Schöler HR. Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol. 2005; 6: 872-81 CrossRef.
Chambers I, Silva J, Colby D, Nichols J, Nijmeijer B, Robertson M, et al. Nanog safeguards pluripotency and mediates germline development. Nature. 2007; 450: 1230-4, CrossRef.
Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003; 113: 643-55, CrossRef.
Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005; 122: 947-56, CrossRef.
Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006; 38: 431-40, CrossRef.
Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, et al. Integration of external signalling pathways with the core transcriptional network in embryonic stem cells. Cell. 2008; 133: 1106-17, CrossRef.
Cole MF, Johnstone SE, Newman JJ, Kagey MH, Young RA. Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. Genes Dev. 2008; 22: 746-55, CrossRef.
Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, Stahl M, et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 1988; 336: 688-90, CrossRef.
Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature. 1988; 336: 684-7, CrossRef.
Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell. 2003; 115: 281-92, CrossRef.
Kim J, Chu J, Shen X, Wang J, Orkin SH. An extended transcriptional network for pluripotency of embryonic stem cells. Cell. 2008; 132: 1049-61, CrossRef.
Feng B, Jiang J, Kraus P, Ng JH, Heng JC, Chan YS, et al. Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol. 2009; 11: 197-203, CrossRef.
Heng JC, Feng B, Han J, Jiang J, Kraus P, Ng JH, et al. The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. Cell Stem Cell. 2010; 6: 167-74, CrossRef.
Dejosez M, Levine SS, Frampton GM, Whyte WA, Stratton SA, Barton MC, et al. Ronin/Hcf-1 binds to a hyperconserved enhancer element and regulates genes involved in the growth of embryonic stem cells. Genes Dev. 2010; 24: 1479-84, CrossRef.
Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature. 2006; 444: 364-8, CrossRef.
van den Berg DL, Snoek T, Mullin NP, Yates A, Bezstarosti K, Demmers J, et al. An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell. 2010; 6: 369-81, CrossRef.
Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010; 143: 313-24, CrossRef.
Lim CY, Tam WL, Zhang J, Ang HS, Jia H, Lipovich L, et al. Sall4 regulates distinct transcription circuitries in different blastocyst-derived stem cell lineages. Cell Stem Cell. 2008; 3: 543-54, CrossRef.
Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol 2008; 10: 353-60, CrossRef.
Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005; 25: 6031-46, CrossRef.
Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113: 631-42, CrossRef.
Li R, Liang J, Ni S, Zhou T, Qing X, Li H, et al. A mesenchymalto-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 2010; 7: 51-63, CrossRef.
Samarvachi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell. 2010; 7: 64-77, CrossRef.
Smith KN, Singh AM, Dalton S. Myc represses primitive endoderm differentiation in pluripotent stem cells. Cell Stem Cell. 2010; 7: 343-54, CrossRef.
Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell. 2008; 134: 521-33, CrossRef.
Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6: 376-85, CrossRef.
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5: 522-31, CrossRef.
Wang Y, Baskerville S, Shenoy A, Babiarz J. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Nat Genet. 2008; 40: 1478-83, CrossRef.
Lichner Z, Páll E, Kerekes A, Pállinger E, Maraghechi P, Bosze Z, et al. The miR-290-295 cluster promotes pluripotency maintenance by regulating cell cycle phase distribution in mouse embryonic stem cells. Differentiation. 2010; 81: 11-24, CrossRef.
Melton C, Judson RL, Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature. 2010; 463: 621-6, CrossRef.
Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008; 320: 97-100, CrossRef.
Rosa A, Spagnoli FM, Brivanlou AH. The miR-430/427/302 family controls mesendodermal fate specification via species-specific target selection. Dev Cell. 2009; 16: 517-27, CrossRef.
Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010; 42: 1113-7, CrossRef.
Smith K, Dalton S. Myc transcription factors: key regulators behind establishment and maintenance of pluripotency. Regen Med. 2010; 5: 947-59, CrossRef.
Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA. 2008; 105: 2883-8, CrossRef.
Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol. 2008; 26: 1276-84, CrossRef.
Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell. 2008; 2: 10-2, CrossRef.
Utikal J, Polo JM, Stadfeld M, Maherali N, Kulalert W, Walsh R, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009; 460: 1145-8, CrossRef.
Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009; 460: 1132-5, CrossRef.
Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009; 460: 1136-9, CrossRef.
Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009; 460: 1140-4, CrossRef.
Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009; 460: 1149-53, CrossRef.
Krizhanovsky V, Lowe SW. The promises and perils of p53. Nature. 2009; 460: 1085-6, CrossRef.
Collado M., Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007; 130: 223-33, CrossRef.
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88: 593-602, CrossRef.
Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res. 2005; 576: 22-38, CrossRef.
Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004; 114: 1299-1307, CrossRef.
Prigione A, Fauler B, Lurz R, Lehrach H, Adjave J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells. 2010; 28: 721-33, CrossRef.
Armstrong L, Tilgner K, Saretzki G, Atkinson SP, Stojkovic M, Moreno R, et al. Human induced pluripotent stem cell lines show stress defense mechanism and mitochondrial regulation similar to those of human embryonic stem cells. Stem Cells. 2010; 28: 661-73, CrossRef.
Chin MH, Mason MJ, Xie W, Volinia S, Singer M, Peterson C, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009; 5: 111-23, CrossRef.
Ghosh Z, Wilson KD, Wu Y, Hu S, Quertermous T, Wu JC. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. Plos One. 2010; 5: e8975, CrossRef.
Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific IPSCs. Nature. 2009; 461: 402-6, CrossRef.
Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2009; 321: 1218-21, CrossRef.
Choi KD, Yu J, Smuga-Otto K, Salvagiotto G, Rehrauer W, Vodyanik M, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells. 2009; 27: 559-67, CrossRef.
Schenke-Layland K, Rhodes KE, Angelis E, Butylkova Y, Heydarkhan-Hagvall S, Gekas C, et al. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. 2008; 26: 1537-46, CrossRef.
Kazuki Y, Hiratsuka M, Takiguchi M, Osaki M, Kajitani N, Hoshiya H, et al. Complete genetic correction of iPS cells from duchenne muscular dystrophy. Molecular Therapy Mol Ther. 2010; 18: 386-93, CrossRef.
Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007; 318: 1920-3, CrossRef.
Hu BY, Weick JP, Yu J, Ma LX, Zhang XQ, Thomson JA, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci USA. 2010; 107: 4335-40, CrossRef.
Sommer CA, Sommer AG, Longmire TA, Christodoulou C, Thomas DD, Gostissa M, et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells. 2010; 28: 64-74, CrossRef.
Lako M, Armstrong L, Stojkovic M. Induced pluripotent stem cell: It looks simple but can looks deceive? Stem Cells. 2010; 28: 845-50, CrossRef.
Newman AM, Cooper JB. Lab-specific gene expression signatures in pluripotent stem cells. Cell Stem Cell. 2010; 7: 258-62, CrossRef.
Guenther MG, Frampton GM, Soldner F, Hockemeyer D, Mitalipova M, Jaenisch R, et al. Chromatin structure and gene expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell. 2010; 7: 249-57, CrossRef.
Chin MH, Pellergrini M, Plath K, Lowry WE. Molecular analyses of human induced pluripotent stem cells and embryonic stem cells. Cell Stem Cell. 2010; 7: 263-9, CrossRef.
Han J, Yuan P, Yang H, Zhang J, Soh BS, Li P, et al. Tbx3 improves the germ-line competency of induced pluripotent stem cells. Nature. 2010; 463: 1096-100, CrossRef.
Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009; 4: 381-4, CrossRef.
Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008; 322: 949-53, CrossRef.
Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science. 2008; 322: 945-9, CrossRef.
Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature. 2009; 458: 771-5, CrossRef.
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, et al. Parkinson’s disease patient- derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009; 136: 964-77, CrossRef.
Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hääänen R, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009; 458: 766-70, CrossRef.
Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell. 2007; 1: 39-49, CrossRef.
Somers A, Jean JC, Sommer CA, Omari A, Ford CC, Mills JA, et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells. 2010; 28: 1728-40, CrossRef.
Lei T, Jacob S, Ajil-Zaraa I, Dubuisson JB, Irion O, Jaconi M, et al. Xeno-free derivation and culture of human embryonic stem cells: current status, problems and challenges. Cell Res. 2007; 17: 682-8, CrossRef.
Hisamatsu-Sakamoto M, Sakamoto N, Rosenberg AS. Embryonic stem cells cultured in serum-free medium acquire bovine apolipoprotein B-100 from feeder cell layers and serum replacement medium. Stem Cells. 2008; 26: 72-8, CrossRef.
Cerdan C, Bendall SC, Wang L, Stewart M, Werbowetski T, Bhatia M. Complement targeting of nonhuman sialic acid does not mediate cell death of human embryonic stem cells. Nat Med. 2006; 12: 1115, CrossRef.
Martin MJ, Muotri A, Gage F, Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med. 2005; 11: 228-32, CrossRef.
Ross PJ, Suhr ST, Rodriguez RM, Cang EA, Wang K, Siripattarapravat K, et al. Human-induced pluripotent stem cells produced under xeno-free conditions. Stem Cells Dev. 2010; 19: 1221-9, CrossRef.
Rodriguez-Piza I, Richaud-Patin Y, Vassena R, Gonzales F, Barrero MJ, Veiga A, et al. Reprogramming of human fibroblast to induced pluripotent stem cells under xeno-free conditions. Stem Cells. 2010; 28: 36-44, CrossRef.
Van den Driessche T, Ivics Z, Izsvák Z, Chuah MK. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood. 2009; 114: 1461-8, CrossRef.
Ivics Z, Li MA, Mátés L, Boeke JD, Nagy A, Bradley A, et al. Transposon-mediated genome manipulation in vertebrates. Nat Methods. 2009; 6: 415-22, CrossRef.
Ivics Z, Hackett PB, Plasterk RH, Izsvák Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997; 91: 501-10, CrossRef.
Hollis RP, Nightingale SJ, Wang X, Pepper KA, Yu XJ, Barsky L. Stable gene transfer to human CD34(þ) hematopoietic cells using the Sleeping Beauty transposon. Exp Hematol. 2006; 34: 1333-43, CrossRef.
Huang X, Wilber AC, Bao L, Tuong D, Tolar J, Orchard PJ, et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood. 2006; 107: 483-91, CrossRef.
Zayed H, Izsvák Z, Walisko O, Ivics Z. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther. 2004; 9: 292-304, CrossRef.
Geurts AM, Yang Y, Clark KJ, Liu G, Cui Z, Dupuy AJ, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 2003; 8: 108-17, CrossRef.
Mátés L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009; 41: 753-61, CrossRef.
Grabundzija I, Irgang M, Mátés L, Belay E, Matrai J, Gogol-Döring A, et al. Comparative analysis of transposable element vector systems in human cells. Mol Ther. 2010; 18: 1200-09, CrossRef.
Xue X, Huang X, Nodland SE, Mátés L, Ma L, Izsvák Z, et al. Stable gene transfer and expression in cord bloodderived CD34þ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood. 2009; 114: 1319-30, CrossRef.
Izsvák Z, Chuah MK, Vandendriessche T, Ivics Z. Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods. 2009; 49: 287-97, CrossRef.
Van den Driessche T, Chuah MK. Moving gene therapy forward with mobile DNA. Hum Gene Ther. 2009; 20: 1559-61, CrossRef.
Belay E, Matral J, Acosta-Sanchez A, Ma L, Quattocelli M, Mates L, et al. Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. Stem Cells. 2010; 28: 1760-71, CrossRef.
Rosa A, Brivanlou AH. Synthetic mRNAs: powerful tools for reprogramming and differentiation of human cells. Cell Stem Cell. 2010; 7: 549-50, CrossRef.
Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Dernck R, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol. 2011; 29: 443-8, CrossRef.
Lakshmipathy U, Davila J, Hart RP. miRNA in pluripotent stem cells. Regen Med. 2010; 5: 545-55, CrossRef.
Chang HM, Gregiry RI. MicroRNAs and reprogramming. Nat Biotechnol. 2011; 29: 499-500, CrossRef.
Shi Y, Zhao Y, Deng H. Powering reprogramming with vitamin C. Cell Stem Cell. 2010; 6: 1-2, CrossRef.
Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell. 2010; 6: 71-9, CrossRef.
Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science. 2008; 321: 699-702, CrossRef.
Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature. 2008; 454: 646-50, CrossRef.
Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 2008; 6: e253, CrossRef.
Loh YH, Agarwal S, Park IH, Urbach A, Huo H, Heffner G, et al. Generation of induced pluripotent stem cells from human blood. Blood. 2009; 113: 5476-9, CrossRef.
Yamanaka S. A fresh look at iPS Cells. Cell 2009; 137: 13-7, CrossRef.
Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, Sommer CA, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010; 7: 20-4, CrossRef.
Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010; 7: 11-4, CrossRef.
Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007; 318: 1920-3, CrossRef.
Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010; 63: 1035-41, CrossRef.
Braun SMG, Jessberger S. Crossing boundaries: Direct programming of fibroblasts into neurons. Cell Stem Cell. 2010; 6: 189-91, CrossRef.
Takeuchi JK, Bruneau BG. Directed transdifferentiation of mouse mesoderm to heart tissue by defined factors. Nature. 2009; 459: 708-12, CrossRef.
Efe JA, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol. 2011; 13: 215-22, CrossRef.
Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell. 2008; 3: 595-605, CrossRef.
Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134: 877-86, CrossRef.
Sun N, Panetta NJ, Gupta DM, Wilson KD, Lee A, Jia F, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci USA. 2009; 106: 15720-5, CrossRef.
Raya A, Rodríguez-Pizà I, Guenechea G, Vassena R, Navarro S, Barrero MJ, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009; 460: 53-9, CrossRef.
Kiskinis E, Eggan K. Progres toward the clinical application of patient-specific pluripotent stem cells. J Clin Invest. 2010; 120: 51-9, CrossRef.
Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell. 2008; 132: 661-80, CrossRef.
Friedrich Ben-Nun I, Benvenisty N. Human embryonic stem cells as a cellular model for human disorders. Mol Cell Endocrinol. 2006; 252: 154-9, CrossRef.
Csete M. Translational prospects for human induced pluripotent stem cells. Regen Med. 2010; 5: 509-19, CrossRef.
Zarzeczny A, Scott C, Hyun I, Bennett J, Chandler J, Chargé S, et al. iPS cells: mapping the policy issues. Cell. 2009; 139: 1032-7, CrossRef.
Condic ML, Rao M. Regulatory issues for personalized pluripotent cells. Stem Cells. 2008; 26: 2753-8, CrossRef.
DOI: https://doi.org/10.18585/inabj.v3i2.138
Copyright (c) 2011 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
